This post has expired! It was posted more than 90 days ago.

Featured JobsThis is a Featured Course!

<- Back

RA Pathogenesis, Patient Goals and Traditional Treatment Course for Moderate-To-Severe Disease

  • : Chatswood NSW 2067

Overview: 
Rheumatoid arthritis (RA) is a chronic, inflammatory disease affecting 1% of the population. If left untreated or undertreated, patients with RA can suffer from joint destruction as well as a wide array of debilitating extra-articular, systemic effects. This module explores the optimisation of the treatment of patients with RA, new and emerging therapies for patients with RA, including IL-6 inhibitors, and the effective use of these newer therapies in clinical practice.

Learning Outcomes: 
Upon completion of this module the participant should be able to:

  • Describe the role of cytokines, particularly IL-6, in the pathogenesis and treatment of RA
  • Assess new data and recent treatment recommendation updates regarding the use of DMARDs for moderate to severe RA
  • Select appropriate, individualised initial and escalation therapies for patients with RA
  • Integrate patient-reported outcomes scales to assess and document treatment effectiveness in clinical practice

 

Disclosure of Conflicts of Interest
Roy Fleischmann, MD, MACR
Consultant/Advisor: Amgen Inc, AbbVie Inc, Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, Pfizer Inc, Sanofi-Regeneron, UCB Inc.
Grant/Research Support: Amgen Inc, AbbVie Inc, Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, Pfizer Inc, Sanofi-Regeneron, UCB Inc.
Speakers' Bureau: Pfizer Inc.

Stephen Hall, MBBS, MMSc, FRACP
No relationships to disclose

Non-faculty:
Christina M. Ohnsman, MD; Jessica Marshall, PharmD; Lou Settembrino; Sandy Breslow; Alison Kemp; and Bernarnd M. Abrams hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

 

This activity has been supported by an independent educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.

Jointly provided by the Elsevier Office of Continuing Medical Education, ASiM, In Vivo Academy Limited, and Reed Medical Education.

Category: 

Musculoskeletal medicine

Components
RA Pathogenesis - education
RA Pathogenesis - evaluation

PRM123
Title
RA Pathogenesis, Patient Goals and Traditional Treatment Course for Moderate-To-Severe Disease
Speciality Classification
Interest Areas
-- GENERAL --
Location
Type
Delivery
Provider Type
RTO
Location
Chatswood NSW 2067
Location Map
Google Map
HealthcareLink